Clinical Trial Update: Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL： A Randomized, Open Phase II Trial [Phase 2]

View source ↗

Summary

A randomized Phase II trial evaluating orelabrutinib plus rituximab versus R-CVP in untreated marginal zone lymphoma (MZL). The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Marginal Zone Lymphoma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Orelabrutinib (orelabrutinib)
• PREDNISONE (Prednisone)
• Rituximab (rituximab)
• Vincristine (vincristine)

Snippet

Sponsor: Fei Li | Conditions: Marginal Zone Lymphoma(MZL) | Phase 2 | Status: RECRUITING